Article

Gene Defect Can Cause Rheumatoid Arthritis

Research on mice has found evidence of a genetic cause of rheumatoid arthritis and could open the door to development of a new line of drugs.

Research on mice has found evidence of a genetic cause of rheumatoid arthritis (RA). The finding, published online this week in Nature Genetics, could open the door to the development of a new line of drugs to treat RA.

Researchers developed mice with myeloid cells that were incapable of producing the A20 gene and found that the rodents had elevated levels of pro-inflammatory cytokines in their blood and joints and developed RA with severe inflammation. A20 is an intracellular negative regulator of the NF-kB transcription factor, which plays an important role in generating inflammatory response. Excessive activation of NF-kB can lead to a range of inflammatory diseases, including RA.

The arthritis in mice deficient in A20 was not dependent on TNF, a cytokine that usually plays a key role in inflammatory diseases such as RA. This is an important finding, since anti-TNF treatment fails to work in about 30% of RA patients. It is possible that drugs targeting A20 could work in such cases.

Sources

Defect in A20 gene expression causes rheumatoid arthritis [EurekAlert]

A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis [Nature Genetics]

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2025 MJH Life Sciences

All rights reserved.